Navigation Links
CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Lazard Capital Markets 7th Annual Healthcare Conference at The St. Regis Hotel in New York City.

Steven G. Anderson, president and CEO of CryoLife, Inc., will present a corporate overview on Tuesday, November 16, 2010 at 4:10 p.m., Eastern Time.

CryoLife's live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page.  An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLifeFounded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  The Company's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  The Company's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  The Company's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife currently distributes HemoStase®, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in many international markets for cardiac, vascular, and general surgery, subject to certain exclusions, although CryoLife has received notice from Medafor, Inc. that it has terminated its HemoStase distribution agreement with CryoLife.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.Media Contact:D. Ashley LeeExecutive Vice President, Chief Financial Officer andChief Operating OfficerPhone: 770-419-3355
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
2. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
3. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
4. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
5. CryoLife Provides Initial 2010 Financial Guidance
6. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
7. CryoLife to Present at Upcoming Investor Conferences in New York
8. CryoLife Reports Record Quarterly Revenues of $28.2 Million
9. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
10. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
11. Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. ... income of $18,800,000, or $0.45 per diluted share, on a ... first quarter ended October 31, 2016. This compares with net ... of $153,779,000 for the first quarter ended October 31, 2015. ... first quarter ended October 31, 2016 to $21,323,000, or $0.51 ...
(Date:12/8/2016)... , Dec. 8, 2016   Mederi Therapeutics Inc . has announced regulatory ... Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director ... , , "We are very ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology:
(Date:12/8/2016)... Fort Myers, FL (PRWEB) , ... December 08, 2016 , ... ... that serves business owners and families in and around the Cape Coral area, is ... the Harry Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank ...
(Date:12/8/2016)... KS (PRWEB) , ... December 08, 2016 , ... ... financial consultation services to families and business owners in and around central Kansas, ... provide assistance to at-risk youth in the region. , Headquartered in Wichita, Youth ...
(Date:12/7/2016)... Alexandria, VA (PRWEB) , ... December 07, 2016 ... ... nation are celebrating the passage of the most comprehensive mental health systems reform ... Congress, the support of the President, and the commitment of our elected officials ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... and deep lines by smoothing and tightening the skin of the face to ... to address facial aging with very little downtime, Silhouette Instalift is a novel, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... it has acquired Presence Technology, S.L. (“Presence”) for a purchase price of ... adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered ...
Breaking Medicine News(10 mins):